Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations

Penn State Hershey Cancer Institute-Clinical Trials Office, Hershey

Hospital of the University of Pennsylvania, Philadelphia

Fox Chase Cancer Center, Philadelphia

Hospital Universitario Puerta de Hierro, Madrid

Winship Cancer Institute of Emory University, Atlanta

Moffitt Cancer Center, Tampa

Hospital Universitario de Salamanca, Salamanca

Tennessee Oncology Sarah Cannon, Nashville

University of Tennessee Cancer Center, Knoxville

Norton Cancer Institute, Louisville

Karmanos Cancer Institute, Detroit

Mayo Clinic, Rochester

University of Rochester, Rochester

University of Chicago, Chicago

University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City

Cancer Care Associates, Tulsa

Charles A. Sammons Cancer Center, Dallas

Houston Methodist Hospital, Houston

The University of Texas M.D. Anderson Cancer Center, Houston

University of Southern California, Norris Comprehensive Cancer Center, Los Angeles

University of California San Francisco-Fresno, Fresno

Swedish Cancer Institute, Seattle

Hospital Universitari Vall d'Hebron, Barcelona

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital Durán i Reynals, Servicio de Oncología, Barcelona